Marker Therapeutics, Inc. announced it has entered into a securities purchase agreement on December 19, 2024. The company will issue 5,031,250 common shares and accompanying warrants to purchase up to 5,031,250 shares of common stock, at a purchase price of $3.20 per share. The pre-funded warrants and the accompanying warrants will be exercisable upon shareholder approval and have a term of five years commencing upon shareholder approval.
The pre-funded warrants will be exercisable at a price of $0.001 per share and the accompanying warrants will have an exercise price of $4.03 per share.
